Literature DB >> 19201486

Serum titers of IgG antibodies against tetanus and diphtheria toxoids and risk of multiple sclerosis.

J Massa1, K L Munger, E J O'Reilly, L I Levin, A Ascherio.   

Abstract

We conducted a prospective nested case-control study among military service members to investigate whether antibodies against tetanus or diphtheria predict multiple sclerosis (MS) risk. Paired T-tests were used to compare means of anti-tetanus and diphtheria toxoids among 56 MS cases and 112 matched controls. Conditional logistic regression was used to estimate odds ratios (OR). There were no differences between the mean serum IgG antibodies against tetanus (p-value 0.28) or diphtheria (p-value 0.45) in the baseline samples. The OR of MS associated with 1 standard deviation difference in antibody titers was 0.76 (95% CI: 0.48-1.21) for tetanus (SD=4.71) and 1.03 (0.73-1.45) for diphtheria (SD=0.87). Results of this study suggest serum IgG antibodies against tetanus or diphtheria are not predictors of MS risk.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19201486      PMCID: PMC2685194          DOI: 10.1016/j.jneuroim.2009.01.006

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  6 in total

Review 1.  Tetanus vaccination and risk of multiple sclerosis: a systematic review.

Authors:  Miguel A Hernán; Alvaro Alonso; Sonia Hernández-Díaz
Journal:  Neurology       Date:  2006-07-25       Impact factor: 9.910

2.  Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis.

Authors:  Kassandra L Munger; Lynn I Levin; Bruce W Hollis; Noel S Howard; Alberto Ascherio
Journal:  JAMA       Date:  2006-12-20       Impact factor: 56.272

3.  Use of prior vaccinations for the development of new vaccines.

Authors:  H M Etlinger; D Gillessen; H W Lahm; H Matile; H J Schönfeld; A Trzeciak
Journal:  Science       Date:  1990-07-27       Impact factor: 47.728

4.  Immunological features in multiple sclerosis.

Authors:  G Lamoureux; N Giard; R Jolicoeur; V Toughlian; M Desrosiers
Journal:  Br Med J       Date:  1976-01-24

5.  Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial.

Authors:  A A Vandenbark; Y K Chou; R Whitham; M Mass; A Buenafe; D Liefeld; D Kavanagh; S Cooper; G A Hashim; H Offner
Journal:  Nat Med       Date:  1996-10       Impact factor: 53.440

6.  Intrathecal synthesis of antibodies to diphtheria and tetanus toxoids in multiple sclerosis patients.

Authors:  A Salmi; M Viljanen; M Reunanen
Journal:  J Neuroimmunol       Date:  1981-09       Impact factor: 3.478

  6 in total
  2 in total

Review 1.  Description and utilization of the United States department of defense serum repository: a review of published studies, 1985-2012.

Authors:  Christopher L Perdue; Angelia A Eick Cost; Mark V Rubertone; Luther E Lindler; Sharon L Ludwig
Journal:  PLoS One       Date:  2015-02-27       Impact factor: 3.240

Review 2.  Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective.

Authors:  Dejan Jakimovski; Bianca Weinstock-Guttman; Murali Ramanathan; Michael G Dwyer; Robert Zivadinov
Journal:  Vaccines (Basel)       Date:  2020-01-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.